Ziaullah Virk, MD
Rheumatology · Hazard, KYNPI 1740267533
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,884 of the $5,252 with a category attached, or 74.0%. 34 manufacturers reported payments, led by Bristol Myers Squibb at 25.6% of the total. Reporting peaked in 2019 at $2,791 and has fallen 76.7% since, to $650 in 2025.
Across 226 payments — averaging $23.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bristol Myers Squibb$1K
- Amgen$872
- UCB, Inc.$391
- Johnson & Johnson$276
- Pfizer$243
- Mallinckrodt Hospital Products Inc.$229
- plus $2K from 28 others
What the payments were for
- Consulting fees$1,08521%
- Food & beverage$3,88474%
- Education$2835%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bristol Myers Squibb | 13 | $1,343 |
| Amgen(2 entities) | 35 | $872 |
| UCB, Inc. | 29 | $391 |
| Johnson & Johnson | 10 | $276 |
| Pfizer | 28 | $243 |
| Mallinckrodt Hospital Products Inc. | 11 | $229 |
| AbbVie | 10 | $196 |
| Novartis | 8 | $174 |
| GSK | 9 | $168 |
| Boehringer Ingelheim | 8 | $152 |
| Corcept Therapeutics | 7 | $130 |
| Boston Scientific | 2 | $129 |
| AstraZeneca(2 entities) | 8 | $124 |
| Genentech USA, Inc. | 7 | $111 |
| Lilly USA, LLC | 5 | $87 |
| Regeneron Healthcare Solutions, Inc. | 3 | $63 |
| Medexus Pharma, Inc. | 2 | $60 |
| Mallinckrodt Enterprises LLC | 3 | $57 |
| La Jolla Pharmaceutical Company | 3 | $48 |
| Sobi, Inc | 3 | $45 |
| Melinta Therapeutics, LLC | 3 | $45 |
| Actelion Pharmaceuticals US, Inc. | 3 | $42 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $38 |
| Abbott | 2 | $33 |
| Biogen | 2 | $33 |
| E.r. Squibb & Sons, L.L.C. | 2 | $28 |
| Coloplast | 1 | $23 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $20 |
| Kowa Pharmaceuticals America, Inc. | 1 | $17 |
| Daiichi Sankyo Inc. | 1 | $17 |
| Antares Pharma, Inc. | 1 | $16 |
| Gilead | 1 | $15 |
| Shionogi Inc | 1 | $14 |
| Merck | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,252 in reported general payments places this provider in the 65th percentile of 81 rheumatology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 17 | $129,820 |
| Hydroxychloroquine Sulfate | 84 | $1,877 |
| Leflunomide | 44 | $1,785 |
| MethotrexateMethotrexate Sodium | 77 | $1,046 |
| Prednisone | 114 | $508 |
| Azathioprine | 11 | $216 |
| Duloxetine Hcl | 12 | $93 |
| Folic Acid | 18 | $64 |
| Celecoxib | 14 | $62 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Hazard
- Jayalakshmi PampatiHazard$2K
- Asad FraserBowling Green$355K
- Rebecca CallisFlorence$272K
- Gary CrumpLouisville$176K
- Benjamin BooneLouisville$80K
- Jacquelyn SmithLouisville$63K
- Neha PansuriaBowling Green$39K
- Timothy LoneskySomerset$32K
- Mansoor AhmedRichmond$29K
- Liza VargheseCrestview Hills$29K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.